- Home
- DVS vs FULC Comparison
DVS vs FULC Comparison
Compare DVS & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVS
- FULC
- Stock Information
- Founded
- DVS 2011
- FULC 2015
- Country
- DVS Canada
- FULC United States
- Employees
- DVS N/A
- FULC N/A
- Industry
- DVS
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- DVS
- FULC Health Care
- Exchange
- DVS Nasdaq
- FULC Nasdaq
- Market Cap
- DVS 401.8M
- FULC 469.0M
- IPO Year
- DVS N/A
- FULC 2019
- Fundamental
- Price
- DVS $4.25
- FULC $9.73
- Analyst Decision
- DVS
- FULC Buy
- Analyst Count
- DVS 0
- FULC 7
- Target Price
- DVS N/A
- FULC $9.14
- AVG Volume (30 Days)
- DVS 1.1M
- FULC 483.6K
- Earning Date
- DVS 11-23-2025
- FULC 11-12-2025
- Dividend Yield
- DVS N/A
- FULC N/A
- EPS Growth
- DVS N/A
- FULC N/A
- EPS
- DVS N/A
- FULC N/A
- Revenue
- DVS N/A
- FULC N/A
- Revenue This Year
- DVS N/A
- FULC N/A
- Revenue Next Year
- DVS N/A
- FULC N/A
- P/E Ratio
- DVS N/A
- FULC N/A
- Revenue Growth
- DVS N/A
- FULC 2752.05
- 52 Week Low
- DVS $2.48
- FULC $2.32
- 52 Week High
- DVS $5.38
- FULC $9.89
- Technical
- Relative Strength Index (RSI)
- DVS 45.31
- FULC 61.99
- Support Level
- DVS $4.25
- FULC $8.45
- Resistance Level
- DVS $4.73
- FULC $9.89
- Average True Range (ATR)
- DVS 0.30
- FULC 0.56
- MACD
- DVS -0.08
- FULC -0.05
- Stochastic Oscillator
- DVS 4.59
- FULC 88.89
About DVS Dolly Varden Silver Corporation Common Shares
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.